These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35608703)

  • 1. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
    Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
    J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
    Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of
    Galbiati A; Bocci M; Ravazza D; Mock J; Gilardoni E; Neri D; Cazzamalli S
    J Nucl Med; 2024 Oct; 65(10):1604-1610. PubMed ID: 39266289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [No Abstract]   [Full Text] [Related]  

  • 9. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
    Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
    Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
    Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
    J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
    Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
    J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of
    Mona CE; Benz MR; Hikmat F; Grogan TR; Lueckerath K; Razmaria A; Riahi R; Slavik R; Girgis MD; Carlucci G; Kelly KA; French SW; Czernin J; Dawson DW; Calais J
    J Nucl Med; 2022 Jul; 63(7):1021-1026. PubMed ID: 34740953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
    Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
    Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the
    Läppchen T; Bilinska A; Pilatis E; Menéndez E; Imlimthan S; Moon ES; Afshar-Oromieh A; Rösch F; Rominger A; Gourni E
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38999044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using
    Baum RP; Schuchardt C; Singh A; Chantadisai M; Robiller FC; Zhang J; Mueller D; Eismant A; Almaguel F; Zboralski D; Osterkamp F; Hoehne A; Reineke U; Smerling C; Kulkarni HR
    J Nucl Med; 2022 Mar; 63(3):415-423. PubMed ID: 34168013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.
    Dekempeneer Y; Massa S; Santens F; Navarro L; Berdal M; Lucero MM; Pombo Antunes AR; Lahoutte T; Van Ginderachter JA; Devoogdt N; D'Huyvetter M
    J Nucl Med; 2023 Dec; 64(12):1941-1948. PubMed ID: 38040444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical translation of a novel FAPI dimer [
    Tan Y; Li J; Zhao T; Zhou M; Liu K; Xiang S; Tang Y; Jakobsson V; Xu P; Chen X; Zhang J
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2761-2773. PubMed ID: 38561515
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Lanzafame H; Mavroeidi IA; Pabst KM; Desaulniers M; Ingenwerth M; Hirmas N; Kessler L; Nader M; Bartel T; Leyser S; Barbato F; Schuler M; Bauer S; Siveke JT; Herrmann K; Hamacher R; Fendler WP
    J Nucl Med; 2024 Jun; 65(6):880-887. PubMed ID: 38724279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.